Binding of fidarestat stereoisomers with aldose reductase

International Journal of Molecular Sciences

Volumn 7, Issue 11, 2006, Pages 519-536

  Kim, Dooil ^a,b   Hong, Suk In ^b   Lee, Dae Sil ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Korea University   (South Korea)

Author keywords

Aldose reductase; Fidarestat; Free energy; Molecular dynamics; Stereospecificity

Indexed keywords

[6 FLUORO 2',5' DIOXOSPIRO[CHROMATIN 4,4' IMIDAZOLIDINE] 2 CARBOXAMIDE]; ALDEHYDE REDUCTASE; FIDARESTAT; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENTROPY; MOLECULAR DYNAMICS; STEREOISOMERISM;

EID: 33947301413     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/i7110519     Document Type: Article

References (51)

1. Laakso, M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999, 48, 937-942.
2. El-Kabbani, O.; Ruiz, F.; Darmanin, C.; Chung, R. P. T. Aldose reductase structures: Implications for mechanism and inhibition. Cell. Mol. Life. Sci. 2004, 61, 750-762.
3. Kador, P. F. The role of aldose reductase in the development of diabetic complications. Med. Res. Rev. 1988, 8, 325-352.
4. Tomlinson, D. R.; Stevens, E. J.; Diemel, L. T. Aldose reductase inhibitors and their potential for the treatment of diabetic complications. Trends Pharmacol. Sci. 1994, 15, 293-297.
5. Lee, A. Y. W.; Chung, S. S. M. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J. 1999, 13, 23-30.
6. Nishimura, C. Y. Aldose Reductase in Glucose Toxicity: A Potential Target for the Prevention of Diabetic Complications. Pharmacol. Rev. 1998, 50, 21-34.
7. Yamagishi, M.; Yamada, Y.; Ozaki, K.; Asao, M.; Shimizu, R.; Suzuki, M.; Matsumoto, M.; Matsuoka, Y.; Matsumoto, K. Biological activities and quantitative structure-activity relationships of spiro[imidazolidine-4, 4′(1′H)-quinazoline]-2,2′,5(3′H)-triones as aldose reductase inhibitors, J. Med. Chem. 1992, 35, 2085-2094.
8. Costantino, L.; Rastelli, G.; Vescovini, K.; Cignarella, G.; Vianello, P.; Del Corso, A.; Cappiello, M.; Mura, U.; Barlocco, D. Synthesis, activity, and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitors. J. Med. Chem. 1996, 39, 4396-4405.
9. Kotani, T.; Nagaki, Y.; Ishii, A.; Konishi, Y.; Yago, H.; Suehiro, S.; Okukado, N.; Okamoto, K. Highly selective aldose reductase inhibitors. 3. Structural diversity of 3-(arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids. J. Med. Chem. 1997, 40, 684-694.
10. Costantino, L.; Rastelli, G.; Gamberini, M. C.; Vinson, J. A.; Bose, P.; Iannone, A.; Staffieri, M.; Antolini, L.; Del Corso, A.; Mura, U.; Albasini, A. 1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J. Med. Chem. 1999, 42, 1881-1893.
11. Costantino, L.; Rastelli, G.; Gamberini, M. C.; Giovannoni, M. P.; Piaz, V. D.; Vianello, P.; Barlocco, D. Isoxazolo-[3,4-d]-pyridazin-7-(6H)-one as a potential substrate for new aldose reductase inhibitors. J. Med. Chem. 1999, 42, 1894-1900.
12. Fresneau, P.; Cussac, M.; Morand, J. M.; Szymonski, B.; Tranqui, D.; Leclerc, G. Synthesis, activity, and molecular modeling of new 2,4-dioxo-5-(naphthylmethylene)-3-thiazolidineacetic acids and 2-thioxo analogues as potent aldose reductase inhibitors. J. Med. Chem. 1998, 41, 4706-4715.
13. Nicolaou, I.; Zika, C.; Demopoulos, V. J. [1-(3,5-Difluoro-4- hydroxyphenyl)-1H-pyrrol-3-yl]phenylmethanone as a Bioisostere of a Carboxylic Acid Aldose Reductase Inhibitor. J. Med. Chem. 2004, 47, 2706-2709.
14. Settimo, F. D.; Primofiore, G.; Settimo, A. D.; Motta, C. L.; Simorini, F.; Novellino, E.; Greco, G.; Lavecchia, A.; Boldrini, E. Novel, highly potent aldose reductase inhibitors: Cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives. J. Med. Chem. 2003, 46, 1419-1428.
15. Pau, A.; Asproni, B.; Boatto, G.; Grella, G. E.; Caprariis, P. D.; Costantino, L.; Pinna, G. A. Synthesis and aldose reductase inhibitory activities of novel thienocinnolinone derivatives. Eur. J. Pharm. Sci. 2004, 21, 545-552.
16. Bruno, G.; Costantino, L.; Curinga, C.; Maccari, R.; Monforte, F.; Nicolò, F.; Ottanà, R.; Vigorita, M. G. Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones. Bioorg. Med. Chem. 2002, 10, 1077-1084.
17. Costantino, L.; Corso, A. D.; Rastelli, G.; Petrash, J. M.; Mura, U. 7-Hydroxy-2-substituted-4-H-1-benzopyran-4-one derivatives as aldose reductase inhibitors: A SAR study. Eur. J. Med. Chem. 2001, 36, 697-703.
18. Singh, S. B.; Malamas, M. S.; Hohman, T. C.; Nilakantan, R.; Carper, D. A.; Kitchen, D. Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants. J. Med. Chem. 2000, 43, 1062-1070.
19. Parenti, M. D.; Pacchioni, S.; Ferrari, A. M.; Rastelli, G. Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach. J. Med. Chem. 2004, 47, 4258-4267.
20. Bohren, K. M.; Grimshaw, C. E.; Lai, C. J.; Harrison, D. H.; Ringe, D.; Petsko, G. A.; Gabbay, K. H. Tyrosin-48 is the proton donor and histidine-110 directs substrate stereochemical selectivity in the reduction reaction of human aldose reductase: enzyme kinetics and crystal structure of the Y48H mutant enzyme. Biochemistry 1994, 33, 2021-2032.
21. Harrison, D. H.; Bohren, K. M.; Petsko, G. A.; Ringe, D.; Gabbay, K. H. The alrestatin double-decker: binding of two inhibitor molecules to human aldose reductase reveals a new specificity determinant. Biochemistry 1997, 36, 16134-16140.
22. Lee, Y. S.; Chen, Z.; Kador, P. F. Molecular modeling studies of the binding modes of aldose reductase inhibitors at the active site of human aldose reductase. Bioorg. Med. Chem. 1998, 6, 1811-1819.
23. Giulio, R.; Luca, C. Molecular dynamics simulations of the structure of aldose reductase complexed with the inhibitor tolrestat. Bioorg. Med. Chem. Lett. 1998, 8, 641-646
24. Kawamura, M.; Hamanaka, N. Development of Eparlestat (Kinedak), aldose reductase inhibitor. J. Synth. Org. Chem. 1997, 37, 787-792.
25. Pfeifer, M. A.; Schumer, M. P.; Gelber, D. A. Aldose reductase inhibitors: The end of an era or the need for different trial designs?. Diabetes 1997, 46, S82-S89.
26. Costantino, L.; Rastelli, G.; Vianello, P.; Cignarella, G.; Barlocco, D. Diabetes complications and their potential prevention: Aldose reductase inhibition and other approaches. Med. Res. Rev. 1999, 19, 3-23.
27. Yasuda, H.; Terada, M.; Maeda, K.; Kogawa, S.; Sanada, M.; Haneda, M.; Kashiwagi, A.; Kikkawa, R. Diabetic neuropathy and nerve regeneration. Prog. Neurobiol. 2003, 69, 229-285.
28. Asano, T.; Saito, Y.; Kawakami, M.; Yamada, N. Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients. J. Diabetes Complicat. 2002, 16, 133-138.
29. Petrova, T.; Steuber, H.; Hazemann, I.; Cousido-Siah, A.; Mitschler, A.; Chung, R.; Oka, M.; Klebe, G.; El-Kabbani, O.; Joachimiak, A.; Podjarny, A. Factorizing selectivity determinants of inhibitor binding toward aldose and aldehyde reductases: structural and thermodynamic properties of the aldose reductase mutant Leu300Pro-fidarestat complex. J. Med. Chem. 2005, 48, 5659-5665.
30. El-Kabbani, O.; Carbone, V.; Darmanin, C.; Oka, M.; Mitschler, A.; Podjarny, A.; Schulze-Briese, C.; Chung, R. P. Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity. J. Med. Chem. 2005, 48, 5536-5542.
31. Oka, M.; Matsumoto, Y.; Sugiyama, S.; Tsuruta, N.; Matsushima, M. A potent aldose reductase inhibitor, (2S,4S)-6-fluoro-2′, 5′-dioxospiro[chroman-4,4′-imidazolidine]-2-carboxamide (Fidarestat): its absolute configuration and interactions with the aldose reductase by X-ray crystallography. J. Med. Chem. 2000, 43, 2479-2483.
32. El-Kabbani, O.; Darmanin, C.; Schneider, T. R.; Hazemann, I.; Ruiz, F.; Oka, M.; Joachimiak, A.; Schulze-Briese, C.; Tomizaki, T.; Mitschler, A.; Podjarny, A. Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with fidarestat and minalrestat: Implications for the binding of cyclic imide inhibitors. Proteins 2004, 55, 805-813.
33. El-Kabbani, O.; Darmanin, C.; Oka, M.; Schulze-Briese, C.; Tomizaki, T.; Hazemann, I.; Mitschler, A.; Podjarny, A. High-Resolution Structures of Human Aldose Reductase Holoenzyme in Complex with Stereoisomers of the Potent Inhibitor Fidarestat: Stereospecific Interaction between the Enzyme and a Cyclic Imide Type Inhibitor. J. Med. Chem. 2004, 47, 4530-4537.
34. Darmanin, C.; Chevreux, G.; Potier, N.; Van Dorsselaer, A.; Hazemann, I.; Podjarny, A.; El-Kabbani, O. Probing the ultra-high resolution structure of aldose reductase with molecular modelling and noncovalent mass spectrometry. Bioorg. Med. Chem. 2004, 12, 3797-3806.
35. Kirkwood, J. G. Statistical mechanics of fluid mixtures. J. Chem. Phys. 1935, 3, 300-313.
36. Mulliken, R. S. Electronic Population Analysis on LCAO-MO Molecular Wave Functions. I, J. Chem. Phys. 1955, 23, 1833-1840.
37. Bayly, C. I.; Cieplak, P.; Cornell, W.; Kollman, P. A. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model. J. Phys. Chem. 1993, 97, 10269-10280.
38. Anisimov, V. M.; Lamoureux, G.; Vorobyov, I. V.; Huang, N.; Roux, B.; MacKerell, Jr., A. D. Determination of Electrostatic Parameters for a Polarizable Force Field Based on the Classical Drude Oscillator. J. Comp. Theor. Chem. 2005, 1, 153-168.
39. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMM: a program for macromolecular energy, minimization, and dynamics calculations, J. Comput. Chem. 1983, 4, 187-217.
40. Brooks III, C. L.; Karplus, M. Deformable stochastic boundaries in molecular dynamics. J. Chem. Phys. 1983, 79, 6312-6325.
41. Mackerell, A. D.; Bashford, D.; Bellott, M.; Dunbrack, R.; Evanseck, J.; Field, M.; Fischer, S.; Gao, J.; Guo, H.; Ha, S.; Joseph, D.; Kuchnir, L.; Kuczera, K.; Lau, F.; Mattos, C.; Michnick, S.; Ngo, T.; Nguyen, D.; Prodhom, B.; Reiher, W.; Roux, B.; Smith, J.; Stote, R.; Straub, J.; Watanabe, M.; Wiorkewicz-Kuczera, J.; Yin, D.; Karplus, M. An all-atom empirical potential for molecular modelling and dynamics study of proteins. J. Phys. Chem. B 1998, 102, 3586-3616.
42. Halgren, T. A. Merck Molecular Force Field: I. Basis, form, scope, parameterization, and performance of MMFF94. J. Comp. Chem. 1996, 17, 490-519.
43. Schmidt, M. W.; Baldridge, K. K.; Boatz, J. A.; Elbert, S. T.; Gordon, M. S.; Jensen, J. J.; Koseki, S.; Matsunaga, N.; Nguyen, K. A.; Su, S.; Windus, T. L.; Dupuis, M.; Montgomery, J. A. GAMESS. J. Comput. Chem. 1993, 14, 1347-1363.
44. Ryckaert, J. P.; Ciccotti, G.; Berendsen, H. J. C. Numerical integration of cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes, J. Comput. Phys. 1977, 23, 327-341.
45. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 1983, 79, 926-935.
46. Tembe, B. L.; McCammon, J. A. Ligand-receptor interactions. Comput. Chem. 1984, 8, 281-283.
47. Wong, C. F.; McCammon, J. A. Dynamics and design of enzymes and inhibitors. J. Am. Chem. Soc. 1986, 108, 3830-3832.
48. Pearhnan, D. A.; Kollman, P. A. A new method for carrying out free energy perturbation calculations: Dynamically modified windows. J. Chem. Phys. 1989, 90, 2460-2470.
49. Wood, R. H. Estimation of errors in free energy calculations due to the lag between the hamiltonian and the system configuration. J. Phys. Chem. 1991, 95, 4838-4842.
50. Hermans, J. Simple analysis of noise and hysteresis in (slow-growth) free energy simulations. J. Phys. Cbem. 1991, 95, 9029-9032.
51. Hermans, J.; Yun, R. H.; Anderson, A. G. Precision of free energies calculated by molecular dynamics simulations of peptides in solution. J. Comput. Chem. 1992, 13, 429-442.